All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Neoadjuvant Chemoimmunotherapy Combination Is Active and Tolerable in Ovarian Cancer

April 13th 2023

Jung-Yun Lee, MD, PhD, discusses the TRU-D trial within the context of prior negative trials to emphasize the need for more effective therapies in advanced-stage ovarian cancer, highlights key findings from TRU-D, and elaborates on future steps for this research.

BI 907828 Demonstrates Early Efficacy, Safety in MDM2-amplified Dedifferentiated Liposarcoma

April 13th 2023

The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.

Enfortumab Vedotin With Pembrolizumab May Usher in New Standard for Treatment of Urothelial Carcinoma

April 13th 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.

Regional Cancer Care Associates Joins The US Oncology Network

April 13th 2023

The US Oncology Network announced that Regional Cancer Care Associates entered into a strategic relationship with The Network effective April 1, 2023

FDA Accepts sBLA for Pembrolizumab Plus Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma

April 13th 2023

The FDA has accepted for review a supplemental biologics license application for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

TIGIT Remains a Tempting Target for Immunotherapy Combinations, Despite Setbacks

April 13th 2023

Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.

Practice-Changing Trials Expand Armamentarium and Improve Guidance in Advanced Breast Cancers

April 13th 2023

Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice.

Individualized Treatment Strategies Strengthen Gynecologic Oncology Armamentarium

April 12th 2023

Marilyn Huang, MD, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease.

Grief and Oncology: Lessons From a Trainee

April 12th 2023

Although grief never leaves us, we learn how to cope. And as we become seasoned oncologists, I hope we can not only empathize with our patients, but learn to manage this storm of emotions, so that ultimately, we can touch so many more lives in the future.

Chemoimmunotherapy Is Associated With Tumor Downstaging in Urothelial Cancer

April 12th 2023

Neoadjuvant pembrolizumab plus gemcitabine with or without cisplatin led to high rates of downstaging to non–muscle invasive urothelial cancer in patients with muscle-invasive urothelial cancer, meeting the primary end points for both cohorts of the phase 1b/2 HCRN GU14-188 trial.

Fox Chase Cancer Center is Holding a ‘Be The Match’ Virtual Event

April 12th 2023

Fox Chase Cancer Center and Temple Health are kicking off National Donate Life Month with a Be The Match virtual event.

NHS Scotland Grants Trastuzumab Deruxtecan Approval for Use in Pretreated HER2+ Metastatic Breast Cancer

April 12th 2023

The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy.

First-line Senaparib Maintenance Meets PFS End Point in Advanced Ovarian Cancer

April 12th 2023

Maintenance therapy with senaparib improved progression-free survival vs placebo for patients with stage III/IV ovarian carcinoma, fallopian tube cancer, or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy, meeting the primary end point of the phase 3 FLAMES trial.

Actionable Subsets of Patients With CRC Drive Progress

April 12th 2023

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Eskander Highlights PFS Outcomes With Pembrolizumab in dMMR/pMMR Advanced Endometrial Cancer

April 12th 2023

Ramez N. Eskander, MD, highlights the potential implications of the NRG GY018 trial as well as safety and efficacy results from the trial.

THIO Followed By Cemiplimab Displays Safety, Tolerability in Advanced NSCLC

April 11th 2023

The sequential combination of THIO plus cemiplimab did not lead to any dose-limiting toxicities or significant treatment-related adverse effects in patients with advanced non–small cell lung cancer.

Research on Current and Emerging HER2-targeted Agents Continues to Advance Breast Cancer Treatment

April 11th 2023

Cynthia X. Ma, MD, PhD, discusses updates in triple-negative breast cancer treatment, recent data on HER2-targeted agents in metastatic and early-stage HER2-positive breast cancer, and the role of CDK4/6 inhibitors and oral selective estrogen receptor degraders in hormone receptor–positive disease.

Retrospective Study Provides Real-World Insight on Ide-cel in R/R Multiple Myeloma With Renal Impairment

April 11th 2023

Surbhi Sidana, MD, discusses the real-world safety and efficacy of ide-cel in patients with multiple myeloma and renal impairment, and emphasizes the importance of including this population in future clinical trials examining novel therapies in this disease.

Ganitumab Plus Interval-Compressed Chemotherapy Fails to Improve EFS in Metastatic Ewing Sarcoma

April 11th 2023

R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.

Dr Stefan C. Grant to serve as Section Chief of Hematology and Medical Oncology

April 11th 2023

Stefan C. Grant, MD, JD, MBA, will serve as the next Chief of the Section of Hematology and Medical Oncology in the John W. Deming Department of Medicine at Tulane University School of Medicine.